

Eli Lilly's and Regeneron's mAb EUA Talk Trigger Expert Prudence on Available COVID-19 Data; Clinical Trials Likely to Be Affected if EUAs Come Through

October 9, 2020

ATTORNEYS

Landmon, Chad

PRACTICE AREAS

FDA

Intellectual Property

Manasi Vaidya

GlobalData

Axinn partner Chad Landmon was quoted in the *GlobalData* article, "Eli Lilly's and Regeneron's mAb EUA Talk Trigger Expert Prudence on Available COVID-19 Data; Clinical Trials Likely to Be Affected if EUAs Come Through."

Click [here](#) to access the article with the permission of "Investigative News team at GlobalData."